FindTrial
Sign In

CGX1321

DRUG2 trials

Sponsors

Curegenix Inc.

Conditions

Bile Duct CarcinomaColorectal AdenocarcinomaEsophageal CarcinomaGI CancerGastric AdenocarcinomaGastrointestinal CancerHepatocellular CarcinomaPancreatic Adenocarcinoma

Phase 1

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Curegenix Inc.GI Cancer, Solid Tumors
Start: 2016-02-29End: 2023-03-31Target: 72Updated: 2022-01-26
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
NCT03507998
Curegenix Inc.Bile Duct Carcinoma, Colorectal Adenocarcinoma, Esophageal Carcinoma +4
Start: 2017-06-17End: 2021-04-01Target: 39Updated: 2020-07-24

Related Papers

A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.
2024-11-014 citations
The Phase I/Ib Trial of WNT Pathway Porcupine Inhibitor CGX1321
Oncology Times2023-07-051 citations
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.
Journal of Clinical Oncology2023-06-0122 citations
Abstract CT117: Synergism between inhibitors of the EGFR-RAS-RAF-MEK pathway and the WNT pathway
Cancer Research2023-04-141 citations